An experimental drug called daraxonrasib is offering new hope for patients with advanced pancreatic cancer, one of the deadliest forms of the disease. In a recent clinical trial, patients taking the daily pill survived a median of 13 months or longer—nearly double the survival time seen with standard chemotherapy. The drug works by blocking malfunctioning RAS proteins that drive tumor growth, a target that has challenged scientists for decades. Researchers also reported fewer severe side effects and improved quality of life for some patients. While daraxonrasib is not a cure and still awaits regulatory approval, experts say it could transform pancreatic cancer treatment and open the door to future therapies.
Read more at ScienceNews
